Aspiriant Risk-Managed Equity Allocation Fund (RMEAX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Aspiriant Risk-Managed Equity Allocation Fund, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Aspiriant Risk-Managed Equity Allocation Fund (RMEAX) has returned -5.53% so far this year and 9.48% over the past 12 months. Over the last ten years, RMEAX has returned 7.22% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Jan 2, 2014, RMEAX's average daily return is +0.03%, while the average monthly return is +0.55%. At this rate, your investment would double in approximately 10.5 years.

Historically, 63% of months were positive and 37% were negative. The best month was Apr 2020 with a return of +7.1%, while the worst month was Mar 2020 at -11.4%. The longest winning streak lasted 14 consecutive months, and the longest losing streak was 5 months.

On a daily basis, RMEAX closed higher 51% of trading days. The best single day was Apr 9, 2025 with a return of +5.8%, while the worst single day was Mar 12, 2020 at -7.4%.

Aspiriant Risk-Managed Equity Allocation Fund has an annualized alpha of -0.11%, beta of 0.58, and R² of 0.74 versus S&P 500 Index. Calculated based on daily prices since January 03, 2014.

• This fund participated in 79.08% of S&P 500 Index downside but only 64.34% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.58 indicates this fund moves significantly less than S&P 500 Index — a genuinely defensive profile with reduced participation in both market rallies and downturns.

RMEAX has an expense ratio of 0.28%, placing it in the medium range.

RMEAX ranks 34 for risk / return — below 34% of mutual funds on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Aspiriant Risk-Managed Equity Allocation Fund (RMEAX) and compare them to a chosen benchmark (S&P 500 Index).

Aspiriant Risk-Managed Equity Allocation Fund provided a 12.49% dividend yield over the last twelve months, with an annual payout of $1.92 per share.

The table displays the monthly dividend distributions for Aspiriant Risk-Managed Equity Allocation Fund. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Aspiriant Risk-Managed Equity Allocation Fund. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aspiriant Risk-Managed Equity Allocation Fund was 23.70%, occurring on Mar 20, 2020. Recovery took 180 trading sessions.

The current Aspiriant Risk-Managed Equity Allocation Fund drawdown is 8.35%.

The chart below shows the rolling one-month volatility.